Recent Advances in Parkinson's Disease

<p>What we can learn from iPSC-derived cellular models of Parkinson’s disease?</p> <p>Maria Claudia Caiazza, Charmaine Lang and Richard Wade-Martins</p> <p>2. Animal models for preclinical Parkinson’s research: An update and critical appraisal</p> <p>M. Angela Cenci and Anders Björklund</p> <p>3. Selective neuronal vulnerability in Parkinson’s disease</p> <p>Patricia Gonzalez-Rodriguez, Enrico Zampese and D. James Surmeier</p> <p>4. Mechanisms of alpha-synuclein toxicity: An update and outlook</p> <p>Inês Caldeira Brás, Mary Xylaki and Tiago Fleming Outeiro</p> <p>5. The role of glia in Parkinson’s disease: Emerging concepts and therapeutic applications</p> <p>Katarzyna Z. Kuter, M. Angela Cenci and Anna R. Carta</p> <p>6. Innate and adaptive immune responses in Parkinson's disease</p> <p>Aubrey M. Schonhoff, Gregory P. Williams, Zachary D. Wallen, David G. Standaert and Ashley S. Harms</p> <p>7. Pathways of protein synthesis and degradation in PD pathogenesis</p> <p>Rebekah G. Langston and Mark R. Cookson</p> <p>8. Endosomal sorting pathways in the pathogenesis of Parkinson’s disease</p> <p>Lindsey A. Cunningham and Darren J. Moore</p> <p>9. New players in basal ganglia dysfunction in Parkinson's disease</p> <p>Sara Meoni, Rubens Gisbert Cury and Elena Moro</p> <p>10. Prodromal PD: A new nosological entity</p> <p>Eva Schaeffer, Ronald B. Postuma and Daniela Berg</p> <p>11. The gut microbiome in Parkinson’s disease: A culprit or a bystander?</p> <p>Ali Keshavarzian, Phillip Engen, Salvatore Bonvegna and Roberto Cilia</p> <p>12. Novel approaches to counter protein aggregation pathology in Parkinson's disease</p> <p>Simon R.W. Stott, Richard K. Wyse and Patrik Brundin</p> <p>13. Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience</p> <p>Tom Foltynie and Dilan Athauda</p> <p>14. Basal ganglia oscillations as biomarkers for targeting circuit dysfunction in Parkinson's disease</p> <p>Per Petersson, Andre</p>